WHWK · Insider Trading
Whitehawk Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by WHWK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | David James Lennon | CHIEF EXECUTIVE OFFICER | A | +387,914 deriv. | — |
| 2026-09-18 | Scott M. Giacobello | CHIEF FINANCIAL OFFICER | A | +236,952 deriv. | — |
| 2026-09-18 | Bryan Ball | See remarks | A | +183,266 deriv. | — |
| 2026-09-18 | Margaret Dugan | Chief Medical Officer | A | +162,500 deriv. | — |
| 2026-09-18 | David Dornan | Chief Scientific Officer | A | +171,774 deriv. | — |
| 2026-09-15 | Margaret Dugan | Chief Medical Officer | A | +162,500 deriv. | — |
| 2026-09-15 | Bryan Ball | See remarks | A | +183,266 deriv. | — |
| 2026-09-15 | Scott M. Giacobello | CHIEF FINANCIAL OFFICER | A | +236,952 deriv. | — |
| 2026-09-15 | David Dornan | Chief Scientific Officer | A | +171,774 deriv. | — |
| 2026-09-15 | David James Lennon | CHIEF EXECUTIVE OFFICER | A | +387,914 deriv. | — |
| 2026-09-11 | Vijay K Iyengar | Director | A | +76,080 deriv. | — |
| 2026-07-30 | Anupam Dalal | Director | A | +1,275,510 | +$5.00M |
| 2026-06-15 | Neil Desai | Director | A | +38,040 deriv. | — |
| 2026-06-15 | Richard E Maroun | Director | A | +38,040 deriv. | — |
| 2026-06-15 | Avoro Capital Advisors LLC | Director | A | +38,040 deriv. | — |
| 2026-06-15 | Mohammad Hirmand | Director | A | +38,040 deriv. | — |
| 2026-06-15 | Caley Castelein | Director | A | +38,040 deriv. | — |
| 2026-06-15 | Baiteng Zhao | Director | A | +38,040 deriv. | — |
| 2026-06-15 | Emma Reeve | Director | A | +38,040 deriv. | — |
| 2026-05-18 | Scott M. Giacobello | CHIEF FINANCIAL OFFICER | A | +38,265 | +$150.00K |
| 2026-05-18 | Bryan Ball | See remarks | A | +51,020 | +$200.00K |
| 2026-05-18 | David James Lennon | CHIEF EXECUTIVE OFFICER | A | +51,021 | +$200.00K |
| 2026-05-18 | Margaret Dugan | Chief Medical Officer | A | +19,132 | +$75.00K |
| 2026-05-18 | Caley Castelein | Director | A | +255,102 | +$1000.00K |
| 2026-05-14 | Avoro Capital Advisors LLC | Director | A | +6,377,714 deriv. | — |
| 2026-04-17 | Scott M. Giacobello | CHIEF FINANCIAL OFFICER | Sell | −218,600 | −$882.03K |
| 2026-04-15 | Bryan Ball | See remarks | Sell | −118,849 | −$427.86K |
| 2026-04-13 | Bryan Ball | See remarks | Sell | −56,596 | −$201.12K |
| 2026-04-10 | David James Lennon | CHIEF EXECUTIVE OFFICER | Sell | −14,500 | −$49.01K |
| 2026-04-08 | David James Lennon | CHIEF EXECUTIVE OFFICER | Sell | −260,427 | −$899.54K |
| 2026-04-03 | David Dornan | Chief Scientific Officer | A | +282,340 deriv. | — |
| 2026-04-03 | Margaret Dugan | Chief Medical Officer | A | +283,157 deriv. | — |
| 2026-04-03 | Scott M. Giacobello | CHIEF FINANCIAL OFFICER | M | +473,902 | — |
| 2026-04-03 | David James Lennon | CHIEF EXECUTIVE OFFICER | MIXED | +748,970 | −$93.47K |
| 2026-04-03 | Bryan Ball | See remarks | M | +366,532 | — |
| 2026-03-10 | Scott M. Giacobello | CHIEF FINANCIAL OFFICER | MIXED | +4,156 | −$8.59K |
| 2026-03-10 | Bryan Ball | See remarks | MIXED | +3,166 | −$6.07K |
| 2026-03-10 | David James Lennon | CHIEF EXECUTIVE OFFICER | MIXED | +11,150 | −$16.88K |
| 2025-12-02 | Margaret Dugan | Chief Medical Officer | A | +705,309 deriv. | — |
| 2025-06-17 | Neil Desai | Director | A | +40,006 deriv. | — |
| 2025-06-17 | Baiteng Zhao | Director | A | +40,006 deriv. | — |
| 2025-06-16 | Emma Reeve | Director | A | +40,006 deriv. | — |
| 2025-06-16 | Anupam Dalal | Director | A | +40,006 deriv. | — |
| 2025-06-16 | Richard E Maroun | Director | A | +40,006 deriv. | — |
| 2025-06-16 | Mohammad Hirmand | Director | A | +40,006 deriv. | — |
| 2025-06-16 | Caley Castelein | Director | A | +40,006 deriv. | — |
| 2025-06-16 | Avoro Capital Advisors LLC | Director | A | +40,006 deriv. | — |
| 2025-04-03 | Bryan Ball | See remarks | A | +733,064 deriv. | — |
| 2025-04-03 | Scott M. Giacobello | CHIEF FINANCIAL OFFICER | A | +947,804 deriv. | — |
| 2025-04-03 | David James Lennon | CHIEF EXECUTIVE OFFICER | A | +1,551,656 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Anupam Dalal | Director | 4,687,042 | $14.67M |
| Caley Castelein | Director | 2,440,794 | $7.64M |
| David James Lennon | CHIEF EXECUTIVE OFFICER | 569,643 | $1.78M |
| Bryan Ball | See remarks | 448,126 | $1.40M |
| Scott M. Giacobello | CHIEF FINANCIAL OFFICER | 333,489 | $1.04M |
| Margaret Dugan | Chief Medical Officer | 19,132 | $59.88K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the WHWK quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.